Syndax
Peter Ordentlich has a Ph.D. in Immunology from the University of Pennsylvania and has a strong background in scientific research. Peter has held various scientific positions at Salk Institute, X-Ceptor Therapeutics, and currently serves as the Chief Scientific Officer and Vice President of Translational Medicine at Syndax Pharmaceuticals.
This person is not in any offices
Syndax
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough The...